Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enatumab in Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
NCT07190261Phase 2Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in warm antibody autoimmune hemolytic anemia (WAIHA). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
gamgertamig
03
Conditions
warm antibody autoimmune hemolytic anemia (WAIHA)
Beyond the preview
Go deeper on NCT07190261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190261.